Kaposi sarcoma-associated herpesvirus (KSHV) is a member of the gammaherpesvirus family. It is the etiological agent of three different human cancers, Kaposi sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castleman disease. The far left end of the KSHV genome encodes a unique transmembrane glycoprotein called K1. K1 possesses the ability to transform rodent fibroblasts and block apoptosis. K1 has also been shown to activate the PI3K/Akt/mTOR pathway in different cells. Using tandem affinity purification, we identified heat shock protein 90b (Hsp90b) and endoplasmic reticulum-associated Hsp40 (Erdj3/DnaJB11), as cellular binding partners of K1. Interactions of K1 with Hsp90b and Hsp40 were confirmed by co-immunoprecipitation in both directions. Furthermore, K1 also interacted with the Hsp90a isoform. We report that smallinterfering RNAs directed against Hsp90 and Hsp40/ Erdj3, as well as pharmacological inhibitors of Hsp90, dramatically reduced K1 expression, suggesting that K1 is a client protein of these chaperones. In addition, both Hsp90 and Hsp40/Erdj3 were essential for K1's antiapoptotic function. Finally, we report that the Hsp90 inhibitors, 17-AAG and 17-DMAG, can suppress the proliferation of KSHV-positive PEL cell lines and exhibited IC 50 values of 50 nM and below.
Introduction
Kaposi sarcoma-associated herpesvirus (KSHV), or human herpesvirus-8, is a gammaherpesvirus. This virus has been implicated as the etiological agent of Kaposi sarcoma (KS) (Chang et al., 1994) and lymphoproliferative diseases of B-cell origin, namely, primary effusion lymphoma (PEL) (Cesarman et al., 1995) and the plasmablastic variant of multicentric Castleman disease (MCD) (Soulier et al., 1995; Gessain et al., 1996) .
The first open-reading frame of KSHV encodes a viral glycoprotein named K1 (Lagunoff and Ganem, 1997) . Both K1 transcript and protein have been detected in KS, PEL and MCD, (Samaniego et al., 2001; Bowser et al., 2002; Lee et al., 2003; Wang et al., 2006) and K1 is expressed at low levels during latency (Wang et al., 2006; Chandriani and Ganem, 2010) . K1 is a transforming protein of KSHV capable of transforming rodent fibroblasts (Lee et al., 1998b) . In addition, K1 transgenic mice develop tumors with features resembling spindlecell sarcomas and malignant plasmablastic lymphoma (Prakash et al., 2002) .
K1 is a 46-kDa type-I transmembrane glycoprotein, which structurally and functionally resembles a B-cell receptor (BCR). In its cytoplasmic tail, K1 contains an immunoreceptor tyrosine-based activation motif or ITAM, that is also found in many immunoglobulin receptors, for example BCR. The K1 ITAM is composed of two appropriately spaced Src-homology 2 binding motifs and is required for BCR activation events (Lee et al., 1998a, b; Lagunoff et al., 1999) . We and others have shown that K1 is capable of activating B-lymphocyte signal transduction and interacting with Syk (Lee et al., 1998a; Lagunoff et al., 1999; Damania et al., 2000) . K1 signaling activity in B cells has been linked to K1 internalization (Tomlinson and Damania, 2008) , and K1 also co-internalizes with the BCR (Tomlinson and Damania, 2008) resulting in the downregulation of BCR surface expression (Lee et al., 2000) .
We previously reported that K1 activates the phosphatidylinositol-3 0 -OH-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway in both B and endothelial cells (Tomlinson and Damania, 2004; Wang et al., 2006) . In addition, we first reported that K1 can prevent Fas-mediated apoptosis through activation of the PI3K/Akt pathway (Tomlinson and Damania, 2004) . In epithelial and endothelial cells, K1 expression induced the secretion of angiogenic factors (Wang et al., 2004) . Cumulatively, these data suggest a paracrine model in which K1-mediated secretion of cytokines is involved in the development of KSHV-associated tumorigenesis and angiogenesis (Wang et al., 2004) .
Molecular chaperones are involved in various cellular processes including protein folding and cell signaling. For example, both heat shock protein (Hsp) 90 and the Hsp40/Hsp70 system act to enhance the Akt pathway that is important for cell survival (Sato et al., 2000; Gao and Newton, 2002) . Hsp40, Hsp70 and Hsp90 are important for the assembly of signaling receptor complexes (Picard et al., 1990; Nathan and Lindquist, 1995; Smith et al., 1995) . Hsp90 and the Hsp40/Hsp70 system have been shown to suppress tumor necrosis factor-and Fas-induced apoptosis (Lewis et al., 2000; Pang et al., 2001) . In addition, Hsp90 overexpression has been detected in a variety of cancers (reviewed by Schmitt et al. (2007) ). The KSHV K1 protein targets similar signaling pathways as Hsp90, for example the PI3K/Akt pathway, and hinders apoptosis by modulating this pro-survival pathway. Hence, the biological roles of Hsp90, Hsp40 and K1 appear to be concordant.
We identified Hsp90b and the endoplasmic reticulum (ER)-associated Hsp40 (Erdj3/DnajB11) as cellular binding partners of K1. Pharmacological inhibition of Hsp90 function reduced expression of the K1 protein.
Similar results were obtained when small-interfering RNAs (siRNAs) were used to knockdown Hsp90b or Hsp40/Erdj3. Knockdown of these chaperones also prevented K1 from promoting cell survival and inhibiting apoptosis. Finally, we report that the Hsp90 inhibitors were very effective in inhibiting the proliferation of KSHV-positive PEL cell lines.
Results
Tandem affinity purification identifies Hsp90b and Hsp40 (Erdj3) as cellular binding partners of K1 To identify cellular binding partners of K1 in the context of mammalian cells, we performed tandem affinity purification (TAP) (Rigaut et al., 1999) . We cloned the FLAG and HA epitopes in tandem right after the signal peptide sequence in the N terminus of K1 using PCR. The double-tagged K1 gene was cloned into the pcDNA3 vector. Stable 293 cells expressing FLAG-HA-K1 (293-K1) or empty vector (293-Vec) were generated by transfection of pcDNA3-FLAG-HA-K1 or pcDNA3 vector into 293 cells, respectively. Cells were selected in 1 mg/ml G418-containing media for 2 weeks.
For TAP, we harvested and lysed 40 confluent T175 flasks per stable cell line in NP40 buffer. The cell lysate was centrifuged and the supernatant was subjected to TAP. The supernatant was first incubated with anti-FLAG resin and then transferred to a spin column. The resin was washed with NP40 buffer and protein complexes were eluted twice with 3 Â FLAG peptide and then pooled. Next, the eluates were incubated with anti-HA resin. This was followed by washes with NP40 buffer and bound proteins were then eluted and resolved by SDS-polyacrylamide gel electrophoresis (PAGE). The gel was Coomassie stained; protein bands unique to K1 expressing cells were excised, trypsin-digested and subjected to matrix-assisted laser desorption/ionizationtime of flight (MALDI-TOF) mass spectrometry analysis ( Figure 1a ).
Mass spectrometry identified Hsp90b and the ERassociated Hsp40 (Erdj3) as cellular binding partners of K1 ( Figure 1a ). Importantly, the specific protein bands for both Hsp90b and Hsp40 were only visible in the K1 lanes, but not in the empty vector (pcDNA3) lanes ( Figure 1a) . Furthermore, the digested peptides fully matched the peptide sequences of Hsp90b and Hsp40 (Erdj3) and achieved very high ion scores ( Figure 1b) .
To confirm the TAP results, we used equivalent micrograms of precleared 293-K1 and 293-Vec lysates to perform immunoprecipitation with anti-FLAG resin beads to immunoprecipitate FLAG-tagged K1 (Figures  2a and c) . The immunoprecipitates were subjected to western blot analysis with anti-Hsp90b (Figure 2a ) or anti-Erdj3 antibody (Figure 2c ). Interactions of K1 with endogenous Hsp90b and Erdj3 were confirmed by reverse co-immunoprecipitation using anti-Hsp90b ( Figure 2b ) or anti-Erdj3/Hsp40 (Figure 2d ), followed by immunoblotting with an anti-FLAG antibody to detect K1 expression. Immunoprecipitation assays performed in both directions strongly corroborated the TAP results, and showed that K1 physically associates with Hsp90b and Erdj3/ER-associated Hsp40. To confirm specificity, we repeated the K1 immunoprecipitation assay with a normal mouse IgG antibody as a negative control. We found that immunoprecipitations using an anti-Flag antibody to pull down K1 co-immunoprecipitated Hsp90b and Hsp40, whereas immunoprecipitation with the control normal mouse IgG antibody did not pull down K1, Hsp90b or Hsp40 (Supplemental Figure 1) .
Because Hsp90a and Hsp90b show 480% identity, and each isoform possesses chaperoning activity (Picard, 2004) , we also investigated whether K1 could interact with Hsp90a. Hsp90b is the constitutive form, whereas Hsp90a is more inducible and has been found in the medium and on the cell surface (Picard, 2004) . We immunoprecipitated K1 using anti-FLAG resin beads from precleared 293-K1 and 293-Vec lysates, and performed western blot analysis using anti-Hsp90a antibody. We found that K1 associated with Hsp90a (Supplemental Figure 2 ), indicating that K1 can interact with both a and b isoforms of Hsp90.
We next investigated whether K1 interacts with Hsps other than Hsp40 and Hsp90. We immunoprecipitated K1 from 293-K1 stable cells with an anti-FLAG antibody. The immunoprecipitates were subjected to western blot analysis with an anti-Hsp70 antibody ( Figure 3a ). We found that K1 failed to interact with ER-associated Hsp70, suggesting that K1 specifically interacts with Hsp90 and Erdj3/Hsp40. Hsp90 possesses intrinsic ATPase activity critical for its chaperoning function (Pearl and Prodromou, 2006) . Apyrase catalyzes the breakdown of ATP and ADP into AMP and inorganic phosphate thereby depleting the ATP content in cells (Pedersen et al., 2003; Zhang and Guy, 2005) . We investigated whether K1's interaction with Hsp90b was dependent on the presence of ATP. We incubated 293-K1 or 293-Vec stable cell lysates with 20 U/ml of apyrase for 30 min, to deplete ATP from the samples (Pedersen et al., 2003) . The ATP-depleted extracts were used to immunoprecipitate K1 and the immunoprecipitates were subjected to SDS-PAGE and immunoblotting with an anti-Hsp90b ( Figure 3b ) or anti-Erdj3/Hsp40 antibody. Notably, ATP depletion by apyrase resulted in less Hsp90b protein being immuno-precipitated with K1 ( Figure 3b ), suggesting that ATP levels modulate K1's interaction with Hsp90b. Interestingly, apyrase treatment did not alter the interaction of K1 with Erdj3/Hsp40, which lacks ATPase activity (data not shown).
Given that K1 expression can be detected in B cells and that K1 perturbs B-cell signaling, we examined if K1 could interact with Hsp90b and Erdj3/Hsp40 in B cells. Lysates from BJAB cells transfected with FLAGtagged K1 or pcDNA3 vector plasmids were subjected to immunoprecipitation using an anti-FLAG antibody to pull down K1 or normal mouse IgG as a negative control ( Figure 3c ). The K1 immunoprecipitates as well as the input lysates were subjected to western blot analysis to detect K1, Hsp90b or Erdj3/Hsp40 (Figure 3c ). Similar to the situation in 293 epithelial cells, we detected specific interactions of Hsp90b with K1 and Erdj3 with K1 in B cells, which suggests that these interactions might be relevant in KSHV-associated B lymphoproliferative diseases such as PEL and MCD.
To corroborate the above findings, we also performed co-localization assays for K1 and Hsp90 or Erdj3 in KSHV-positive BCBL-1 cells. Briefly, BCBL-1 were fixed, permeabilized and then stained with anti-K1 antibody and anti-Hsp90/anti-Erdj3 antibody and examined by confocal microscopy. We found that K1 colocalizes with Hsp90 and Erdj3/Hsp40 (Supplemental Immunoprecipitation reactions were subjected to SDS-PAGE followed by western blotting with an anti-Hsp90b antibody. Input lysates showed the presence of Hsp90b in all cell lysates, and K1 protein in the 293-K1 cell lysate. (b) Reverse co-immunoprecipitations were also performed. Lysates from 293-Vec or 293-K1 stable cells were immunoprecipitated with an anti-Hsp90b antibody. Immunoprecipitations were subjected to SDS-PAGE and western blot analysis with an anti-FLAG antibody to detect K1 protein expression. Input lysates showed the presence of Hsp90b in all cell lysates, and K1 protein in the 293-K1 cell lysate. These data are representative of at least three independent experiments. (c and d) Identical co-immunoprecipitations were performed as indicated in a and b, respectively, except that anti-Hsp40 antibody was used instead of Hsp90b antibody.
Hsp90 and Hsp40 modulate K1 expression and function KW Wen and B Damania Figure 3 ). In addition, we also performed immunohistochemistry on PEL tumor sections (Supplemental Figure 4 ). We found that both K1 and Hsp90 proteins were detected by immunohistochemical staining of tumor sections (Supplemental Figure 4 ).
Hsp90b and Erdj3/Hsp40 associate with the N-terminal domain of K1 To gain insight into the function and topology of the interaction, we used a panel of FLAG-tagged K1 domain deletion constructs (DC, C-terminal deletion; DTM, transmembrane deletion; DN, N-terminal deletion) to determine the K1 domain that interacted with Hsp90b and the ER-associated Hsp40. Expression plasmids for the K1 deletion mutants, the FLAG-tagged wild-type K1 and the control pcDNA3 vector were transiently transfected into 293 cells. Protein lysates were harvested 48 h after transfection. Co-immunoprecipitations for K1 with Hsp90b and Hsp40 were performed as described above for Figure 2 . FLAGtagged K1 was immunoprecipitated with anti-FLAG beads, followed by immunoblotting with anti-Hsp90b ( Figure 4a ) or anti-Hsp40/Erdj3 antibody (Figure 4c ). Hsp90b and Hsp40 were detected in all of the samples expressing K1 except for the sample expressing the K1DN mutant. In addition, the reverse immunoprecipitation of Hsp90b ( Figure 4b ) or Hsp40 ( Figure 4d ) followed by western blot analysis with anti-FLAG antibody also suggested that the K1DN mutant protein does not interact with Hsp90b or Hsp40. Collectively, our data suggests that the N-terminal domain of K1 interacts with the Hsp90b and Hsp40/Erdj3 molecular chaperones.
K1 protein expression is dependent on Hsp90 activity
As Hsps are molecular chaperones that confer protein stability to their client proteins, we next tested whether the chaperoning activity of Hsp90 affected K1 protein expression. The ansamycin antibiotic, geldanamycin (GA), was used to inhibit the ATPase activity of Hsp90, an activity that is essential for its chaperoning function. Thus, GA prevents the transfer of client proteins to Hsp90. GA inhibits all isoforms of Hsp90, but not of Hsp40. After GA treatment, client proteins of Hsp90 are degraded by the proteasomal machinery (Whitesell et al., 1997; Xu et al., 2003) . We treated stable 293-K1 or 293-Vec cells with 1 mM GA, or vehicle (DMSO), for 6 h. Lysates were harvested and subjected to immunoblotting. We found that pharmacological inhibition of Hsp90 with 1 mM GA in 293-K1 cells dramatically decreased K1 protein levels when compared to DMSO treatment ( Figure 5a ). Expectedly, the protein level of phosphorylated Akt (S473), a known client protein of Hsp90 (Xu et al., 2003) , was also diminished in the presence of GA. Immunoprecipitation reactions were subjected to SDS-PAGE followed by western blotting with an anti-Hsp90b antibody. (c) Identical coimmunoprecipitations were performed as described in Figure 2a , except that protein lysates from BJAB B cells transfected with pcDNA3.1 vector or K1 expression plasmid were immunoprecipitated with anti-FLAG antibody. Immunoprecipitates were subjected to SDS-PAGE followed by western blotting with an anti-Hsp90b antibody. Input lysates showed the presence of Hsp90b in all cell lysates, and K1 protein in the 293-K1 cell lysate.
Immunoprecipitation was also performed with species-matched normal IgG antibody as a negative control.
We previously reported that K1 can activate and phosphorylate Akt in B and endothelial cells (Tomlinson and Damania, 2004; Wang et al., 2006) . Here we observed the same phenomenon in epithelial cells, where 293-K1 cells showed increased p-Akt (S473) levels compared to 293-Vec samples (Figure 5b ). We next tested whether K1 had any effect on the endogenous levels of Hsp90b and ER-associated Hsp40. Western blot analysis of 293-K1 and 293-Vec cell lysates did not show an appreciable difference in Hsp90b and Hsp40 protein abundance, albeit the total Akt and p-Akt (S473) levels were increased in K1-expressing 293 cells (Figure 5b ).
siRNA-mediated depletion of Hsp90b and ER-associated Hsp40/Erdj3 reduces K1 protein expression
To confirm the results obtained with pharmacological inhibition of Hsp90, and to rule out any off-target effects of GA that may lead to decreased K1 protein levels, we performed genetic knockdown of Hsp90b and Erdj3/ER-associated Hsp40 using siRNAs. Briefly, 293-K1 cells were transfected with 200 pmol of pooled Hsp90b-targeting siRNAs or a control luciferase-targeting siRNA (siLUC). Cells were harvested 48 h after transfection and the protein lysates were subjected to western blot analysis. The Hsp90b siRNAs robustly depleted the endogenous level of Hsp90b without affecting endogenous actin levels ( Figure 5c ). Similar to GA treatment, Hsp90b siRNA expression resulted in a reduction of K1 protein expression compared to control luciferase siRNA (Figure 5c ). Hsp90b siRNA knockdown also led to reduced total Akt and p-Akt (S473) levels.
We also tested if K1 protein level is dependent on ERassociated Hsp40/Erdj3 expression. 293-K1 cells were transfected with a pool of three different siRNAs directed against Hsp40/Erdj3 (siHsp40 in Figure 5d ) or the irrelevant siLUC for 48 h. The protein lysates were then subjected to immunoblotting. As shown in Figure 5d , the pooled siHsp40 siRNAs effectively reduced the endogenous level of Hsp40/Erdj3 compared to the siLUC-transfected sample, but did not alter endogenous actin levels. We found that siRNA knockdown of Hsp40/Erdj3 also inhibited K1 protein expression and was accompanied by a slight reduction of the total Akt and p-Akt (S473) levels (Figure 5d ). Taken together, these data suggest that Hsp90 and Hsp40/ Erdj3 are required for the protein stability of K1, and that K1 is a client protein of Hsp90 and the ERassociated Hsp40/Hsp70 chaperone system. Lysates were immunoprecipitated with anti-FLAG resin. Immunoprecipitation reactions were subjected to SDS-PAGE and western blotting with an anti-Hsp90b antibody. Input lysates showed the presence of Hsp90b in all cell lysates and the presence of K1 mutants in the K1 mutant transfected cells. (b) Reverse co-immunoprecipitations were also performed. Lysates from cells transfected with the vector control or the K1 panel of mutants were immunoprecipitated with an anti-Hsp90b antibody. Immunoprecipitation reactions were subjected to western blot analysis with an anti-FLAG antibody to detect K1 protein expression. Input lysates showed the presence of Hsp90b in all cell lysates and the presence of K1 mutants in the K1 mutant transfected cells. These data are representative of at least three independent experiments. (c, d) Identical co-immunoprecipitations were performed as indicated in a, b, respectively, except that anti-Hsp40 antibody was used instead of Hsp90b antibody. In a-d, arrows indicate the N-terminal deletion mutant of K1.
Interaction with Hsp90b and Erdj3 regulates K1 anti-apoptotic function We next interrogated whether Hsp90b and Erdj3's association with K1 can modulate its function. To examine the impact of Hsp90b or Erdj3 knockdown on K1 function, we tested the ability of K1 to prevent Fasmediated apoptosis (Tomlinson and Damania, 2004; Wang et al., 2007; Berkova et al., 2009) in the presence of Hsp90b and/or Erdj3 siRNAs described above. 293-K1 or 293-Vec cells were transfected with 200 pmol of siRNAs targeting Erdj3 and/or Hsp90b, or K1. To control for any undesirable effect of siRNA transfection on apoptosis, we used nontargeting siRNA as well as a GFP-targeting siRNA for comparison. At 36 h after siRNA transfection, the cells were subjected to Fas-receptor antibody stimulation for 12 h to stimulate Fas-receptor dependent apoptosis. Equivalent number of cells were harvested, lysed and subjected to a fluorescence-based assay that measures caspase-3 activity as a readout of apoptosis (Tomlinson and Damania, 2004) . Caspase-3 activity in the antibody-stimulated 293-K1 cells was calculated as a percent of the caspase-3 activity in the antibody-stimulated 293-Vec control cells. Figure 6a shows the percent of activated caspase-3 detected in the Fas antibody-stimulated 293-K1 cells compared to the stimulated 293-Vec cells with the same siRNA transfection. Overall, the 293-K1 cells displayed a 50% decrease in caspase-3 activation compared to the 293-Vec cells, after Fas-receptor stimulation. This is in concordance with what we and others have previously reported (Tomlinson and Damania, 2004; Wang et al., 2007; Berkova et al., 2009) . Transfection of either Hsp90b siRNA, Hsp40/Erdj3 siRNA, GFP siRNA or nontargeting siRNA into the 293-K1 cells, followed by anti-Fas-receptor antibody stimulation, yielded similar levels of caspase-3 activity in these cells (Figure 6a ) indicating that single knockdown of either the Hsp90b or Hsp40 chaperone did not alter K1's ability to prevent Fas-mediated apoptosis. However, when both Hsp90b siRNAs and Hsp40/Erdj3 siRNAs were co-transfected into 293-K1 and 293-Vec cells, the 293-K1 cells now displayed similar levels of caspase-3 activity as the 293-Vec cells (Figure 6a ), suggesting that both Hsp90b and Erdj3 are required for K1 to exert its anti-apoptotic function, and that knockdown of both chaperones increases the sensitivity of K1-expressing cells to Fasmediated apoptosis. The absolute data for the caspase-3 assays are provided in Supplemental Figure 5 .
To look at the role of Hsp90b and Hsp40/Erdj3 on K1's ability to prevent cell death, we repeated the experiment with Fas antibody stimulation but extended the incubation time with the antibody to 18 h (instead of 12 h) to analyze cell death of 293-K1 versus 293-Vec cells transfected with the indicated siRNAs (Figure 6b ). Cells were stained with Trypan blue and the numbers of viable and dead cells were counted under microscopy in four different fields. Cell death in the Fas antibodystimulated 293-K1 cells was calculated as a percentage of cell death seen in 293-Vec cells stimulated with the same antibody. Overall, the trend in Figure 6b recapitulates that in Figure 6a . Supplemental Figure 5b shows the absolute number of dead cells seen in Fas antibodystimulated 293-K1 cells compared to 293-Vec cells. As a control, a western blot of K1 expression in 293-K1 cells transfected with siLUC versus K1 siRNA is depicted in Figure 6c to show effective knockdown of K1 protein levels in the K1 siRNA transfected cells.
Hsp90 inhibitors decrease the proliferation of KSHVpositive PEL-derived B-cell lines in vitro Because Hsp90 and Hsp40 regulate the protein expression and anti-apoptotic function of K1, we wanted to determine if Hsp90 inhibitors can block proliferation of KSHV-positive PEL cells. PEL cells have previously been shown to express K1 transcripts and protein at low levels (Bowser et al., 2002; Lee et al., 2003) . We treated PEL cells with DMSO (vehicle control) or 50 nM of the GA-derived Hsp90 inhibitors, 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), that are currently in clinical trials (Ivy and Schoenfeldt, 2004; Goetz et al., 2005) for 0, 24, 48, 72 and 96 h. We found that both inhibitors suppressed the growth of KSHV-harboring PEL cell lines, BCP-1, BCBL-1 and JSC-1, in an MTS-based cell proliferation assay (Figure 7a ). We also determined the half-maximal inhibitory concentration (IC 50 ) of 17-AAG and 17-DMAG in BCP-1, BCBL-1 and JSC-1 cell lines 72 h after treatment. The IC 50 of 17-AAG and 17-DMAG were B50 and B10 nM, respectively, in all three cell lines (Figures 7b and c) . These IC 50 values are consistent with other tumor cell lines that are dependent on Hsp90 (Hollingshead et al., 2005) . Hence, 17-AAG and 17-DMAG can effectively inhibit KSHV-infected PEL cell lines in vitro. We also investigated the effects of 17-DMAG on 293-K1 cells compared to 293-Vec cells. 293-K1 and 293-Vec cells (1 Â 10 6 ) were incubated with 17-DMAG and a Trypan blue exclusion assay was performed at 24, 48 and 72 h after treatment. We found that at all three time points tested, there were more live cells present in the 293-K1 cells compared to the 293-Vec cells. This suggests that K1 confers a survival advantage to 293 cells on Hsp90 inhibition (Supplemental Figure 6 ) and that higher concentrations of drug are required to inhibit K1-expressing 293 cells compared to 293 cells that do not express the K1 protein.
To address whether the decrease in proliferation of 50 nM 17-AAG and 17-DMAG is due to the induction of cell death, we treated the same three PEL lines above with 50 or 500 nM of each inhibitor, or DMSO, for 0, 24, 48, 72 and 96 h and assessed cell viability by a Trypan blue exclusion assay. We found that 500 nM of 17-AAG and 17-DMAG induced an increase in cell death of PEL cells over time (Figure 8a ). In agreement with this observation, we have found that the LC 50 values of 17-AAG and 17-DMAG in BCP-1 are 464.4 and 523.5 nM, respectively (Figures 8b and c) at 72 h after treatment. We also confirmed that similar to GA treatment (Figure 5a ), treatment of 293-K1 cells with 500 nM of 17-DMAG inhibited K1 protein expression compared to 293-K1 cells treated with vehicle (DMSO) (Figure 8d ).
On the basis of the inhibitory effect of 17-AAG/17-DMAG on PEL cell proliferation, we speculated that both Hsp90 inhibitors may alter the cell cycle of PEL. We performed cell-cycle analysis to address this possibility. JSC-1 and BCBL-1 were treated with 50 nM 17-AAG and 17-DMAG for 48 h, and then subjected to propidium staining and flow cytometry. Both PEL cell lines displayed significant G0/G1 arrest and suppressed DNA synthesis on Hsp90 inhibition (Figure 9 ). 17-DMAG was a stronger inhibitor of the cell cycle than 17-AAG (Figure 9) . Thus, the cell-cycle arrest phenotype seen in the presence of 17-AAG and 17-DMAG corroborates with the inhibition of cell proliferation we observed in the MTS assay for the different PEL cell lines (Figure 7) .
Discussion
KSHV K1 is a viral oncoprotein that has been shown to transform cells, induce tumor formation (Damania et al., 1999; Prakash et al., 2002) as well as inhibit apoptosis (Tomlinson and Damania, 2004; Wang et al., 2007; Berkova et al., 2009 ). Furthermore, the K1 protein activates the PI3K/Akt signaling pathway in endothelial cells and B cells (Tomlinson and Damania, 2004; Wang et al., 2006) . However, relatively little is known about how K1 protein expression and function are modulated. Using TAP, we identified Hsp90b and the ER-associated Hsp40/Erdj3 protein as cellular partners of K1. This was corroborated by co-immunoprecipitations that confirmed these protein-protein interactions. Importantly, we have shown that K1's interaction with Hsp90b (but not Hsp40/Erdj3) is dependent on the presence of ATP. We also found that K1 can interact with the Hsp90a isoform. Interestingly, both Hsp90 and K1 have individually been shown to modulate the phosphorylation or function of several important signaling molecules such as VEGF receptor (Le Boeuf et al., 2004; Wang et al., 2004 Wang et al., , 2006 , Akt (Sato et al., 2000; Tomlinson and Damania, 2004; Wang et al., 2006) , Lyn (Prakash et al., 2002 (Prakash et al., , 2005 Lee et al., 2005; Trentin et al., 2008) , PDK1 (Fujita et al., 2002; Wang et al., 2006) , BCR (Lee et al., 2000; Shinozaki et al., 2006; Tomlinson and Damania, 2008) and mTOR (Ohji et al., 2006; Wang et al., 2006) . In KSHV, as well as other herpesviruses, Hsp90 also regulates subcellular trafficking and function of viral proteins (Field et al., 2003; Burch and Weller, 2005; Livingston et al., 2008) . A novel finding of this report is that K1 appears to be a viral client protein of Hsp90 and the ER-associated Hsp40/Hsp70 system. This is particularly intriguing as it suggests that the protein expression of the K1 viral oncogene can be manipulated with existing Hsp90 inhibitors as well as siRNA/small-hairpin RNAs targeting Hsp90 and/or Hsp40/Erdj3 chaperones. In addition, we have shown that K1 interacts and colocalizes with Hsp90 and Hsp40/Erdj3 in B cells. K1 and Hsp90 expression can also be detected in PEL tumors. Thus, our data validate Hsp90 as an important therapeutic target for treating KSHV-associated lymphomas.
Using the Hsp90 inhibitor GA, we showed that Hsp90 ATPase activity and chaperoning function is required for optimal expression of K1. GA inhibits all the known Hsp90 homologues, including cytosolic/extracellular Hsp90a and Hsp90b, as well as Grp94/Gp96 (ER-associated Hsp90), and Trap1 (mitochondria-associated Hsp90). Thus, it is possible that Hsp90 homologues other than Hsp90a and Hsp90b may also associate with K1 and modulate its expression and function. Similar to GA treatment, genetic knockdown of either Hsp90b or Hsp40/Erdj3 using siRNA also dramatically reduced K1 protein expression.
We found that depletion of both endogenous Hsp90b and ER-associated Hsp40 negated the ability of K1 to prevent Fas-mediated apoptosis. However, depletion of only Hsp90b or Hsp40 by itself had no effect. One explanation is that knockdown of both Hsp90b and Hsp40 reduced K1 expression levels more robustly than single knockdowns of these proteins. A second possibility is that there are two different pools of K1 whose expression and/or function are regulated by Hsp90b and Hsp40. K1 has been shown to be expressed on the plasma membrane as well as in the ER (Lee et al., 2000) . Because Hsp90b is predominantly cytosolic and Hsp40/Erdj3 is ER associated, one may speculate that these different pools of K1 are topologically distinct. Hence, knockdown of the ER-restricted chaperone may reduce K1 levels in the ER, but not affect cytosolic or cell-surface levels of K1, and vice versa. Thus, single knockdowns of either Hsp90b or Hsp40/Erdj3 may not have reduced K1 protein levels in all cellular compartments to the same extent as double knockdowns of both these chaperones.
We found that K1 could interact with both Hsp90b and Hsp90a isoforms. Besides being cytosolic, Hsp90a (Eustace et al., 2004; Li et al., 2007) and Hsp90b (Sidera et al., 2004) have been found on the cell surface, that is extracellularly. Thus, the N-terminal domain of K1 may co-internalize with extracellular Hsp90. Because K1 internalization has been linked to its signaling function (Tomlinson and Damania, 2008) , Hsp90 likely has a role in chaperoning K1 as it is endocytosed. In addition, because the N-terminal domain of K1 interacts with Hsp90b, it is also possible that Hsp90b interacts with the K1 N terminus during de novo biogenesis of K1 protein when the growing peptide is transiting from the cytoplasm to the ER. Indeed, Hsp90b has been shown to be involved in the protein translation of the BCR (Shinozaki et al., 2006) . Furthermore, because the ER-associated Hsp40/Erdj3 functions as a co-chaperone with Hsp70/BiP for unfolded/nascent proteins, including the unassembled immunoglobulin heavy chain (Shen and Hendershot, 2005) , Hsp40/Erdj3 may also participate in the folding of newly synthesized/unfolded or misfolded K1 within the ER.
Our data show that Hsp90 inhibition by 17-AAG and 17-DMAG at low concentrations results in decreased cell proliferation and G0/G1 arrest, albeit at higher concentrations, 17-AAG and 17-DMAG can also induce cell death of KSHV-positive PEL cells. A potential mechanism for these observations is that Hsp90 inhibition leads to a decrease in K1 protein expression, and this has a two pronged effect on the PI3K/Akt/mTOR pathway. This is because Hsp90 inhibition suppresses activation of the PI3K/Akt/mTOR pathway that is normally activated by the K1 viral oncoprotein, and indirectly by Hsp90 through stabilization of and maintenance of Akt kinase activity. Because PI3K, Akt and mTOR are cell survival kinases, inhibition of Hsp90 destabilizes K1 protein and suppresses its ability to enhance PEL cell proliferation and cell survival through this pathway. This model would predict that Hsp90 inhibition would lead to decreased proliferation of cells that do not express K1 compared to proliferation of cells that do express K1. Indeed, we observed that more 293-K1 cells survived in the presence of Hsp90 inhibitor compared to 293-Vec cells (Supplemental Figure 6 ).
We also speculate that there are several other KSHV proteins that use molecular chaperones to modulate their expression and function. Field et al. (2003) previously reported that the KSHV latent viral FLICE inhibitory protein requires Hsp90 to complex with IkB kinase and activate the nuclear factor-kB pathway. Here we report that both Hsp90 and Hsp40 chaperones were needed for K1 protein expression and its anti-apoptotic function. Taken together, our studies provide additional rationale for using Hsp90 inhibitors to treat PEL and other KSHV-related malignancies.
Materials and methods
Cell culture 293-K1 and 293-Vec stable cells were established and maintained in 1 mg/ml G418 selection in Dulbecco's modified Eagle's medium medium supplemented with 10% fetal bovine serum in 5% CO 2 . BCP-1, JSC-1 and BCBL-1 cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamate, 0.05 mM 2-mercaptoethanol and 0.075% sodium bicarbonate in 5% CO 2 .
Antibodies
Rabbit anti-K1 antibody was a kind gift from Dr Jae Jung. Anti-Hsp90 (ab1429) and anti-Hsp70 (ab2787) antibodies were purchased from Abcam (Cambridge, MA, USA). Anti-Hsp90a and anti-Hsp90b antibodies were purchased from Stressgen (SPS-771 and SPA-843) (Ann Arbor, MI, USA). Anti-Hsp40 (DNAJB11) antibody was obtained from Sigma (HPA010814) (St Louis, MO, USA). Anti-Akt and anti-phospho-Akt (S473) were purchased from Cell Signaling (Danvers, MA, USA) whereas anti-actin antibody was purchased from Santa Cruz Biotechnology (C16) (Santa Cruz, CA, USA). Anti-FLAG M2 resin was obtained from Sigma for immunoprecipitation of K1. Normal mouse IgG (sc-2025), normal rabbit IgG (sc-2027) and protein A/G PLUS-Agarose (sc-2003) were purchased from Santa Cruz Biotechnology. Horseradish peroxidaseconjugated anti-ECS antibody used for FLAG immunoblotting was purchased from Bethyl (A190-101P) (Montgomery, TX, USA).
Inhibitors and siRNAs
GA, 17-AAG and 17-DMAG were purchased from Invivogen (San Diego, CA, USA). Stealth siRNAs targeting Hsp90b and Erdj3 were purchased from Invitrogen (Carlsbad, CA, USA). Anti-Luc siRNA-1, Accell nontargeting siRNA pool and GFP siRNA duplex were purchased from Thermo Scientific (Waltham, MA, USA). The siRNAs directed against K1 (CCACAACAATTGCAGGATTUU and CCATGCAACCAC ACATAAAUU) were designed by Dharmacon (Lafayette, CO, USA) siDESIGN Center Custom siRNA Design Tool and purchased from Dharmacon.
Tandem affinity purification
We generated the FLAG HA tandem tagged K1 construct (TAP-K1) by QuikChange site-directed mutagenesis. The oligonucleotides 5 0 -ACGACGACAAGGGTACCTACCCATA CGACGTCCCAGACTACGCTCTTTATGTGCTATCGTC-3 0 and 5 0 -GACGATAGCACATAAAGAGCGTAGTCTGGGA CGTCGTATGGGTAGGTACCCTTGTCGTCGT-3 0 were used to introduce the HA epitope sequence between FLAG and K1 at the N terminus. pcDNA3-K1 and empty pcDNA3 vector were transfected into 293 cells using FuGENE 6 reagent (Roche, Indianapolis, IN, USA) and selected with 1 mg/ml G418 to establish 293-K1 and 293-Vec stable cells, respectively. Forty confluent T175-flasks of each cell line were harvested and washed twice in cold phosphate-buffered saline. Cells were pelleted and stored at À80 1C. 293-K1 and 293-Vec stable cell pellets were thawed and lysed in NP40 buffer supplemented with phenylmethylsulfonyl fluoride, protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktails 1 and 2 (Sigma). The lysates were pelleted and the supernatants (20 mg/ml) were subjected to TAP using the FLAG HA Tandem Affinity Purification Kit (Sigma). After TAP, we eluted the samples in 2 Â Laemmli sample buffer and resolved them on a 12% NuPAGE Novex Bis-Tris Mini Gel (Invitrogen). The gel was Coomassie stained and submitted to the UNC Proteomics Center for mass spectroscopy. Protein bands unique to K1 expressing cells were excised, trypsin-digested and subjected to MALDI-TOF mass spectroscopy analysis.
Immunoprecipitation
For each reaction, we harvested confluent cells in a 10-cm dish, washed them twice in ice cold phosphate-buffered saline and then lysed them in RIPA buffer supplemented with phenylmethylsulfonyl fluoride, and protease and phosphatase inhibitors. Extract was incubated with 1 mg of primary antibody at 4 1C for 4 h and Protein A/G PLUS-Agarose (or FLAG resin) was added to the lysate and incubated at 4 1C overnight. After binding, we washed the resins 4 Â with RIPA buffer. Immunoprecipitated protein complexes were eluted in 2 Â Laemmli sample buffer (or 3 Â FLAG peptide).
MTS assay
The MTS assay was performed according to the manufacturer's protocols (Promega, Madison, WI, USA). Cells were incubated for 4 days with indicated amounts of drug at a seeding density of 1 Â 10 5 cells per ml in triplicate. Absorbance was read daily at a wavelength of 490 nm.
Caspase-3 assay Cells were transfected with siRNAs using Superfect (Qiagen, Valencia, CA, USA). At 36 h after transfection, the transfected cells were stimulated with anti-Fas cross-linking antibody (clone CH11; Millipore, Billerica, MA, USA) at 0.2 mg/ml in 1% fetal bovine serum, and cells were harvested 12 h later (Tomlinson and Damania, 2004) . Apoptosis was analyzed by using an ApoAlert caspase-3 fluorimetric assay kit from Clontech (Mountain View, CA, USA). Absorbance was read on a FLUOstar Optima fluorometric plate reader with a 400-nm excitation and 505-nm emission filter.
Cell-cycle analysis
Cells fixed in 70% ethanol were resuspended in phosphatebuffered saline with 20 mg/ml propidium iodide and 200 mg/ml RNaseA. Flow cytometric analysis was performed with a Becton Dickinson FACScan (Franklin Lakes, NJ, USA) and ModFit LT V3.2.1 program (Verity Software House, Topsham, ME, USA).
